Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial

Hepatology. 2023 Oct 1;78(4):E72-E73. doi: 10.1097/HEP.0000000000000532. Epub 2023 Jul 17.

Authors

Ya-Fei Hu¹, Han-Fei Gu^{1

2}, Yan-Wen Jin^{1

3}, Fu-Yu Li^{1

3}

Affiliations

¹ Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu, China.
² Regenerative Medicine Research Center, West China Hospital of Sichuan University, Chengdu, China.
³ Department of Biliary Disease Research Center, West China Hospital of Sichuan University, Chengdu, China.

PMID: 37459557
DOI: 10.1097/HEP.0000000000000532

No abstract available

Publication types

Randomized Controlled Trial
Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bile Duct Neoplasms* / drug therapy
Bile Ducts, Intrahepatic
Capecitabine / therapeutic use
Chemotherapy, Adjuvant
Cholangiocarcinoma* / drug therapy
Cisplatin / therapeutic use
Deoxycytidine / therapeutic use
Gemcitabine
Humans

Substances

Capecitabine
Cisplatin
Gemcitabine
Deoxycytidine